Home > News & Media > News
Communication starts here.
2018.04
TWi is marketing Cephelexin Oral Suspension in partnership with a leading Taiwanese manufacturer
2017.12
Court Dismisses Patent Challenge to TWi's Paragraph IV ANDA Filing for a Generic Equivalent to Axiron®
2017.11
TWi's ANDA of Bupropion HCI ER Tablets has been approved by US FDA
2017.08
TWi Pharmaceuticals, Inc. Comments on Oxtellar XR® Ruling
2017.08
TWi successfully launches generic Guanfacine HCl ER Tablets in TWi label
2017.06
TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Tecfidera
2017.04
TWi Signed a Cooperation Agreement with Intech for US Inhalation Market
2017.02
TWi Confirms Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Axiron
2017.01
TWi Settles Patent Challenge Relating to Its Paragraph IV ANDA Filing for a Generic Equivalent to Restasis
2016.12
TWi Bio is officially listed on Emerging Market of Taipei Exchange

 

Pages:1 - 2 - 3 - 4 - 5 - 6 - 7 - 8« Pre · Next »